Difference between revisions of "Thoracic SMARCA4-deficient undifferentiated tumour"

From Libre Pathology
Jump to navigation Jump to search
 
Line 11: Line 11:


DDx:
DDx:
*[[Small round blue cell tumours]].
*Large cell [[Lymphoma]]s.
*[[Small cell carcinoma of the lung]].
*[[Small cell carcinoma of the lung]].
*Basaloid [[squamous cell carcinoma]].
*Other [[small round blue cell tumours]].


==IHC==
==IHC==

Latest revision as of 20:17, 21 August 2025

Thoracic SMARCA4-deficient undifferentiated tumour is poorly differentiated malignancy of the thorax.[1]

General

  • It was debated whether it is a poorly differentiated carcinoma or a sarcoma.[2]
  • WHO recognized entity as of 2021.[3]

Microscopic

Features:

DDx:

IHC

  • SMARCA4 (BRG1) loss (~75% of cases) or strongly reduced (~25% of cases) - definitional.
  • AE1/AE3 -ve or focal.
  • Synaptophysin +ve.
  • Chromogranin -ve.

See also

References

  1. Shinno Y, Ohe Y (March 2024). "Thoracic SMARCA4-deficient undifferentiated tumor: current knowledge and future perspectives". Jpn J Clin Oncol 54 (3): 265–270. doi:10.1093/jjco/hyad175. PMID 38117955.
  2. Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD (February 2020). "SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas". J Thorac Oncol 15 (2): 231–247. doi:10.1016/j.jtho.2019.10.023. PMC 7556987. PMID 31751681. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556987/.
  3. "Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy". Lung Cancer 189: 107471. March 2024. doi:10.1016/j.lungcan.2024.107471. PMID 38306886.